항체-약물 접합체(ADC)
성숙
항체의 표적 선택성에 세포독성 약물(페이로드)을 링커로 연결해, 암세포에만 약물을 정밀 전달하는 표적 항암 기술.
전망 혈액암을 넘어 고형암으로 빠르게 확장 중. 차세대 링커·페이로드와 이중 표적 ADC가 다음 물결.
개발 기업
관련 뉴스
전체 →최신 연구
전체 →Science advances
알부민 결합에 의한 (177)Lu 표지 HER2 Fab 방사성 결합체의 약동학 및 치료 효과 개선Cancer letters
정정: "글리코실화된 CEACAM6을 표적하는 중쇄 항체-약물 접합체가 뇌 전이 종양 성장을 억제" [Cancer Lett. 648, (2026) 218463]Journal of cancer research and clinical oncology
전이성 유방암에서 인간 영양막 세포 표면 항원 2(TROP-2) 발현Clinical cancer research : an official journal of the American Association for Cancer Research
Tisotumab Vedotin 치료 환자의 분자 프로파일링은 임상 활성과 연관된 면역 경로를 규명한다Expert opinion on biological therapy
비소세포폐암에 대한 항체-약물 결합체 기반 병용 치료 전략의 진전Blood advances
Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALLESMO open
Next-generation precision oncology in microsatellite stable colorectal cancer: integrated targeting beyond RAS and RAFmAbs
Setting expectations for current and future directions of native mass spectrometry in the biopharmaceutical industryGynecologic oncology
Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinomaNature
Modular in vivo antibody-ADC click to reverse drug resistance in tumoursMedComm
The Expression Patterns of Antibody-Drug Conjugate-Related Markers in Urothelial Carcinoma With Histological VariantsInternational journal of women's health
Treatment Sequencing in Platinum-Resistant Epithelial Ovarian Cancer After MIRASOL, KEYNOTE-B96, and ROSELLA
진행 중 임상
전체 →- 2상모집 예정SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates
- 1/2상모집 중A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- 2상모집 중HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
- 단계 미표기모집 예정A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting
- 3상모집 예정NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
- 1/2상모집 중A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
- 1/2상모집 중A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- 1상모집 중A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
- 2상모집 중PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
- 초기 1상모집 중A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
- 1/2상모집 중A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- 3상모집 중A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.